ImmuneOnco Biopharma, founded in June of 2015 in Zhangjiang High-Tech Park of Shanghai, China, is an early stage biopharmaceutical company dedicated to the development and commercialization of novel cancer immunotherapy products designed to reverse cancer cell-induced immune inhibition and to actively eradicate cancer cells.
To achieve the goals, we established several solid platforms harnessing two types of innate immune cells, macrophages and natural killer (NK) cells to fulfill the cancer-killing task. Macrophages play a critical role in fighting cancer through phagocytosis followed by presenting of tumor antigen to T cells which will destroy the tumor antigen-expressing cells. However cancer cells are smart and can always find a way to evade the surveillance, such as by over-expressing CD47 which interacts with signal regulatory protein
alpha (SIRP) on macrophages and results in an inhibition of phagocytosis toward cancer cells. We are developing a pipeline of product candidates which we believe will reverse cancer cell-induced phagocytosis inhibition.
NK cells are natural arms of the body for fighting against viral infection as well as cancer, in a way different from cytotoxic T cells that need to recognize MHC on target cells. NK cells can kill the target cells directly without the requirement for MHC recognition. Our pipeline involves technology platforms enabling us to establish target-activated NK (TANK™) cell therapy that will be applied to the treatment of both leukemia and solid tumors.
ImmuneOnco is actively advancing the pipeline of proprietary platform-based product candidates targeting a broad range of indications in cancer.